B-Cell Immune Modulation With Controlled Antigen Valency and Form
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying B cell autoimmunity rely heavily on transgenic mouse models that do not adequately address antigen valency and form, and fail to consider the relevance of antigens to known autoimmune diseases, leading to ineffective modulation of immune responses in conditions like diabetes.
Innovation Solution
The use of oligomeric anti-insulin antibodies with high affinity and monospecificity for insulin, combined with a specific ratio of monovalent and polyvalent antigen particles, to modulate B-cell mediated immune responses and induce protective IgM responses, thereby controlling autoimmune reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If transgenic mouse models are used to study B cell autoimmunity, then research can be conducted on autoimmune diseases, but the models fail to adequately address antigen valency and form and do not consider antigen relevance to known autoimmune diseases
Solution Approach 1:
The patent applies parameter changes by systematically varying antigen valency (monovalent vs. multivalent) and antigen form (soluble vs. complexed) to study their effects on B cell responses. This resolves the contradiction by making the model adaptable to different autoimmune disease contexts while maintaining reliability in addressing antigen properties through controlled parameter variation.
2Productivity
If complexed multivalent antigens are used, then strong IgG type antibody B-cell response is induced, but harmful autoimmune responses may be exacerbated
Solution Approach 1:
The patent applies local quality by differentiating between different types of antigen presentations (monovalent vs. multivalent, soluble vs. complexed) and their specific effects on different antibody types (IgM vs. IgG). This allows selective induction of protective IgM responses while avoiding harmful IgG-mediated autoimmune responses, resolving the contradiction between response productivity and harmful effects.
3Object-generated harmful factors
If monovalent antigenic structures are used, then IgG responses are suppressed and protective IgM responses are induced, but the ability to induce strong protective responses may be limited
Solution Approach 1:
The patent applies inversion by using monovalent antigenic structures to induce protective IgM responses instead of the conventional approach of using multivalent antigens to induce IgG responses. This resolves the contradiction by inverting the typical immunogenic strategy to achieve both suppression of harmful IgG responses and induction of protective IgM responses.
Data Source
AI summary
The invention pertains to methods and means for the targeted modulation of B-cell mediated immune responses by bringing into contact a B-cell with a specific ratio of soluble single monovalent antigens and complexed multivalent antigens. The targeted modulation of B-cell immunity can be used in mammals for the diagnosis and therapy of various conditions associated with antibody-mediated immunity. Such conditions include proliferative disorders such as cancer, autoimmune disorders, pathogenic infections, inflammatory diseases, allergies and food intolerances. The invention is predicated on the observation that complexed multivalent antigenic structures induce a strong IgG type antibody B-cell response while surprisingly monovalent antigenic structures harbour the ability to suppress such IgG responses, or even induce in the case of autoantigens protective IgM responses, in particular protective oligomeric anti-insulin antibodies. The invention in this regard offers methods, compositions, therapeutics, diagnostics and food additives.